{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:55:22Z","timestamp":1762998922155},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,3,26]],"date-time":"2012-03-26T00:00:00Z","timestamp":1332720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The objective of this study was to investigate the management of suspected fungal nail infections by general practitioners (GPs) and determine whether guidance is sought when submitting specimens for investigation or treating cases. Questionnaires were sent to all GPs (<jats:italic>n<\/jats:italic>\u2003=\u20032420) served by five Health Protection Agency (HPA) collaborating laboratories in the South West of England. A total of 769 GPs responded \u2013 topical and oral antifungals were never used by 29% and 16% of GPs respectively. When antifungals were prescribed, topicals were normally given because of the severity of infection (32%); Amorolofine (53%) was the preferred choice. Oral antifungals were most often prescribed after receipt of a laboratory report (77%); Terbinafine was the preferred choice (86%). Seventy percent of GPs would only treat a suspected nail infection with oral antifungals after sending a sample for investigation, yet 27% never waited for a microscopy report before prescribing oral antifungal treatment. GPs routinely send specimens from suspected fungal nail infections for microbiological investigation, yet treatment is often prescribed before a result is received. With clinical signs of fungal infections often non\u2010specific, GPs should rely on laboratory results before prescribing expensive and lengthy antifungal treatments. Laboratories could further reduce antifungal use by including guidance on microscopy and culture reports.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2012.02183.x","type":"journal-article","created":{"date-parts":[[2012,3,26]],"date-time":"2012-03-26T23:59:31Z","timestamp":1332806371000},"page":"476-482","source":"Crossref","is-referenced-by-count":2,"title":["Developing best practice for fungal specimen submission \u2013 fungal audit of general practice"],"prefix":"10.1111","volume":"55","author":[{"given":"G.","family":"Lasseter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A. M.","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Yoxall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kibbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Health Protection Agency GP Microbiology Laboratory Use Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,26]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.12.005"},{"key":"e_1_2_6_3_2","unstructured":"Clinical knowledge summaries. Clinical Topics: Fungal nail infection.2009.http:\/\/www.cks.nhs.uk\/fungal_nail_infection#\u2010388836[accessed online January 2011]."},{"key":"e_1_2_6_4_2","first-page":"1","article-title":"Analysis of the dermatophyte species isolated in the British Isles between 1980 and 2005 and review of worldwide dermatophyte trends over the last three decades","volume":"44","author":"Borman AM","year":"2006","journal-title":"Med Mycol Month"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022426309340"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05242.x"},{"volume-title":"Fungal Skin & Nail Infections: Diagnosis & Laboratory Investigation, Quick Reference Guide for Primary Care","year":"2009","author":"Health Protection Agency","key":"e_1_2_6_7_2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00320.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2010.03.003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01480-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03362.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2007.01444.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701243418"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701657187"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X8100100304"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011203"},{"volume-title":"Antibiotic National Charts \u2013 Antibiotics, Year Ending 2010","author":"NHS Prescription Services","key":"e_1_2_6_17_2"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.353"},{"volume-title":"British National Formulary","year":"2011","author":"Joint Formulary Committee","key":"e_1_2_6_19_2"},{"volume-title":"Curanail\u00ae","year":"2010","author":"Galderma (UK) Ltd","key":"e_1_2_6_20_2"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.03.021"},{"key":"e_1_2_6_22_2","unstructured":"ABPI Medicines Compendium.Summary of product characteristics for lamisil tablets 250\u2003mg. Electronic Medicines Compendium.2009a; Datapharm Communications Ltd. URLhttp:\/\/www.medicines.org.uk\/emc\/medicine\/1290[accessed online December 2010]."},{"key":"e_1_2_6_23_2","unstructured":"ABPI Medicines Compendium.Summary of product characteristics for sporanox capsules. Electronic Medicines Compendium.2009b; Datapharm Communications Ltd. URLhttp:\/\/www.medicines.org.uk\/emc\/medicine\/7395[accessed online December 2010]."},{"key":"e_1_2_6_24_2","unstructured":"Clinical Knowledge Summaries.Patient information leaflet: fungal nail infections. URLhttp:\/\/www.cks.nhs.uk\/patient_information_leaflet\/fungal_nail_infection#462509000[accessed online December 2010]."}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2012.02183.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2012.02183.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:17:09Z","timestamp":1698635829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2012.02183.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,26]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1439-0507.2012.02183.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2012.02183.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"type":"print","value":"0933-7407"},{"type":"electronic","value":"1439-0507"}],"subject":[],"published":{"date-parts":[[2012,3,26]]}}}